Publications by authors named "Sofie Korn"
Article Synopsis
- Chronic hand eczema is a painful, inflammatory condition affecting the hands and wrists, impacting patients' quality of life and ability to work; the DELTA 1 and DELTA 2 trials aimed to evaluate the effectiveness and safety of delgocitinib cream against a placebo.* -
- Both studies were randomized, double-blind, and involved adult participants with moderate to severe chronic hand eczema, comparing the effects of twice-daily applications of delgocitinib cream to a placebo for 16 weeks, focusing on achieving a clear or almost clear skin condition.* -
- Results showed that significantly more patients treated with delgocitinib achieved treatment success compared to the placebo group, with notable differences observed in both trials
Background: Chronic hand eczema (CHE) is a burdensome disease, and new well-documented, safe and efficacious treatments are warranted. In a recent CHE phase IIa trial, the pan-Janus kinase (JAK) inhibitor delgocitinib in an ointment formulation was found to be efficacious and well tolerated.
Objectives: This trial assessed the dose response, efficacy and safety of delgocitinib cream in CHE.
The analysis of recurrent events in the presence of terminal events requires special attention. Several approaches have been suggested for such analyses either using intensity models or marginal models. When analysing treatment effects on recurrent events in controlled trials, special attention should be paid to competing deaths and their impact on interpretation.
View Article and Find Full Text PDF